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Abstract
Background The hundreds of thousands of patients found to have
a potentially malignant pulmonary nodule each year are faced with
tremendous uncertainty regarding what the nodule is and how it
should be evaluated.
Objective To explore patients’ responses to the detection and eval-
uation of a pulmonary nodule.
Design Qualitative study based on four focus-group discussions.
We performed inductive analysis using principles of grounded the-
ory to identify themes relating to responses to the nodule and
strategies to manage uncertainty.
Setting and participants Twenty-two patients from two medical
centres who were undergoing surveillance for an indeterminate
pulmonary nodule.
Results Patient responses to an indeterminate pulmonary nodule
were varied and evolved over time. Although almost all patients
reported an initial fear about cancer, subsequent depictions of the
nodule diverged into four types defined on two dimensions: cogni-
tive (‘it’s cancer’ vs. ‘I don’t know what it is’ vs. ‘it’s nothing seri-
ous’) and emotional (anxiety vs. equanimity). Most eventually
accepted that the nodule was unlikely to be malignant; however,
some remained anxious, convinced the nodule could turn into can-
cer at any time and should be aggressively monitored for life.
Patients used results of surveillance tests as well as their own strat-
egies (e.g. vigilance for symptoms, information-seeking, contem-
plating and controlling modifiable risk factors, avoidance, faith) to
manage uncertainty.
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Conclusions Surveillance for a pulmonary nodule can weigh heav-
ily on some patients for months or years. Our findings may help
clinicians prepare patients with a newly detected pulmonary nod-
ule for the burden of the prolonged uncertainty of surveillance.
Introduction
With the increasing sensitivity of imaging tests,
physicians are able to find minute abnormali-
ties, which previously would have remained
undetected. In many cases, technologic
advances have outpaced the evidence on the
clinical significance of these abnormalities and
how they should be managed. This type of
uncertainty dominates the clinical scenario fac-
ing doctors and their patients in the increas-
ingly common situation of having found a
pulmonary nodule that may or may not be
lung cancer – a problem that now affects more
than 150 000 Americans each year.1
For most patients with a small pulmonary
nodule, clinical practice guidelines2,3 recom-
mend a conservative approach of radiographic
surveillance to avoid the potential harms of
biopsy.4 If the nodule does not grow during
2–3 years of surveillance, it is assumed to be
benign. Guidelines calling for surveillance of
low-risk nodules offer an effective strategy for
doctors to manage the uncertainty these nod-
ules present with a routine approach. Yet,
patients may not accept surveillance as
‘routine’. For patients, the often unexpected
discovery of a ‘spot’ on the lung may be alarm-
ing and the uncertainty ominous. Surveys of
patients with an indeterminate pulmonary nod-
ule, whether detected incidentally or through
lung cancer screening, indicate that some
experience substantial distress and reduced
health-related quality of life.5–7 Providers may
be familiar with the intense distress that some
women with abnormal mammogram results
experience8–10; however, for these women, the
uncertainty about cancer is typically resolved
within a few weeks by a definitive biopsy. By
contrast, most patients with an indeterminate
pulmonary nodule must live through years of
uncertainty.
To counsel patients on the evaluation pro-
cess once a nodule has been found, providers
should be aware of what surveillance of an
indeterminate pulmonary nodule will mean for
patients. Yet, there has been little in-depth
research on the patient’s experience of living
with a pulmonary nodule that may or may not
be lung cancer. We sought to characterize how
patients with an indeterminate pulmonary nod-
ule respond to the prolonged uncertainty that
surveillance entails, how their perceptions of
the nodule evolve over time and what strategies
they used to manage uncertainty.
Methods
We conducted focus groups from April–
November 2010 with patients who were
undergoing surveillance for an indeterminate
pulmonary nodule, to elicit patients’ accounts
of their experiences and their commentaries on
similar patients’ experiences. Eligible partici-
pants were English speakers aged 18–89 years.
Participants were recruited from primary care
and pulmonary clinics from two geographically
distinct United States academic medical cen-
ters, one that serves a racially diverse, econom-
ically disadvantaged urban population, and the
other, a referral center for a rural population.
Two focus groups were conducted at each site.
We identified potential participants through
solicitation of names from providers; review of
referrals to pulmonary clinic for nodule evalua-
tion; and search of problem lists and CT
reports for the phrase ‘pulmonary nodule’.
After receiving permission from the treating
provider, we invited patients to attend a 2-h
focus group to discuss their experiences, offer-
ing a $40 gift card as a token of appreciation.
All participants provided informed consent
according to protocols approved by each site’s
institutional review board.
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Two facilitators [a pulmonologist (RSW) and
medical sociologist (JAC)] led discussions, cov-
ering both pre-specified content areas (Table 1)
and topics raised by focus group participants.
We asked participants to tell their stories of
how they responded to the discovery and sur-
veillance of their pulmonary nodule. The con-
tent of the discussions was largely determined
by how participants answered when asked to
describe what happened when they first heard
about ‘the spot in your lung’, what they
thought about it and how their thoughts chan-
ged over time. Discussions were audio-recorded
and transcribed verbatim.
The goal of our analysis was to characterize
patients’ perceptions of their pulmonary
nodules, including their evolving depictions of
the nodule and the ways in which they managed
the uncertainty associated with surveillance.
Our analysis was interpretive and inductive,
according to the precepts of grounded the-
ory.11,12 Two investigators (RSW, JAC) devel-
oped and revised preliminary thematic content
categories through close readings of transcripts,
which were then systematically coded with cate-
gory labels by RSW. Repeated comparisons of
passages within and between categories and par-
ticipants resulted in the iterative formulation of
thematic summaries, each supported by quota-
tions, that were critically reviewed by the team.
Differing interpretations were discussed until
consensus was achieved. After four focus
groups, we achieved thematic saturation.
Results
Overview
The 22 participants described experiences with
pulmonary nodules that were identified 2–28
Table 1 Pre-specified topics and sample questions to be
covered during focus groups
Doctor–patient communication
Tell me what happened when you first heard about the
spot in your lung. What did your doctor say? What was
that like for you?
Did your doctor talk to you about the different possibilities
of what the spot in the lung might be? What did the
doctor say about that?
Did your doctor mention cancer or give you a sense of
how likely that was? Was that helpful?
Did your doctor talk about the next steps they would do
to figure out what the spot in the lung is? Do you have a
sense of what the plan is? Were you involved in deciding
on the plan?
Are there things that your doctor did that you really liked
or that you wish your doctor had done differently when
they first told you about the spot in your lung?
If you have questions about the spot in your lung, do you
feel like that is something you can talk to your doctor
about?
Knowledge about nodule and its evaluation
What do you think the spot in the lung is?
How likely do you think it is that the spot in the lung will
turn out to be cancer?
How long do you think you’ll have to have CAT scans to
check on the spot in the lung?
Do you ever think the spot in your lung is causing
symptoms?
Experience of living with pulmonary nodule
When you first found out about the nodule, what was
going through your head? Has that changed? How do you
feel about the spot in your lung now?
What is the hardest thing about living with a spot in the
lung?
How often does the spot in your lung cross your mind?
Are there things that bother you about the tests you’ve
had to get done for the spot in the lung?
Have you told your loved ones about the spot in your
lung? How did they react?
Table 2 Characteristics of focus group participants
Mean age, years (SD) 60.7 (15.4)
Female, % 86
Race/ethnicity, %
White 77
Black 18
Hispanic 4.5
Current or former smoker, % 68
Median nodule size, millimetres (SD) 6 (5.4)
Sub-centimetre nodule, % 77
Median time since diagnosis,
months (range)
10 (2–28)
Context of nodule discovery, %
Work-up of pulmonary symptom 18
Incidental finding during work-up
of non-pulmonary issue
82
Lung cancer screening 0
Follow-up testing of nodule/evaluation plan, %
Surveillance with serial imaging 100
Bronchoscopy and/or biopsy 23
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(median = 10) months previously (Table 2).
For most (82%), the diagnosis was incidental
to a work-up for a non-pulmonary issue. All
were undergoing radiographic surveillance;
23% had also undergone bronchoscopy or
biopsy that had not revealed a definitive diag-
nosis. Their average age was 61 years, most
were female, and 68% were current or former
smokers. Median nodule size was 6 mm.
Participants described depictions of their
pulmonary nodules that evolved over time and
varied with respect to two dimensions: cogni-
tive and emotional. Cognitively, the nodule
was construed in three ways. Initially, it was a
clear threat (i.e. ‘cancer’) for virtually all par-
ticipants. For some, the nodule later became
‘nothing serious’. However, most participants
were expressly cognizant of the nodule’s uncer-
tain identity; they did not know what it was or
what threat, if any, it posed. Emotional
responses ranged from fear (for all who defined
the nodule as ‘cancer’) to equanimity (for all
who considered the nodule to be ‘nothing
serious’). Thus, from the participants’
accounts, we identified four depictions of inde-
terminate pulmonary nodules (Fig. 1) and a
typical trajectory of their responses over time,
as indicated by the arrow. Participants also dis-
cussed their ways of managing the uncertainty
of the nodule.
Evolving depictions of the nodule
Depiction 1. Cognitive: It’s Cancer; Emotional:
Fear/Worry
For almost all participants, the clinician’s dis-
closure of a nodule evoked frightening images
of cancer: ‘if anybody was told they had a nod-
ule on their lungs, …the majority of the people
would have this big C-word running through
their head’ [Pt17]. This response occurred irre-
spective of obvious risk factors: current, former
and never smokers all had an immediate
impression that the nodule was lung cancer.
For most, the nodule was unexpected, an
incidental finding when the patient presented
with a non-pulmonary issue (e.g. chest pain,
pre-operative evaluation for cholecystectomy).
The news was upsetting, even shocking:
you expect to be healthy. … The reason why I
got the CAT scan in the first place was because
of my liver. … Then they said, “well, there’s
something on your lung.” I’m like, “well, that’s
not what you’re supposed to be looking at!” …
It was like somebody putting a ball and chain
and a yoke around your neck. [Pt7]
It was really scary, especially since the abdominal
MRI only showed the bottom of my lungs. So
I’m like, ‘ok what’s in the rest of my lungs? [Pt5]
Whereas most participants described subse-
quently moving to a less ominous understand-
ing of their nodule, some remained convinced
it was cancer and persisted in a heightened
state of fear and worry for weeks or months:
Even though I didn’t have an official diagnosis,
… a certain part of me accepted that I had lung
cancer. And I just thought that’s what it
was. [Pt5]
The conviction that the nodule was cancer
led some to make lifestyle changes to make the
most of what they perceived as a limited time
remaining with their families:
I actually gave notice at my job because I work
anywhere from 55 to 60 hours a week. … I’m
going to take a job that’s 40 hours a week and
spend more time with my kids. … I don’t know
what’s going to happen and I don’t want to miss
anymore. [Pt20]
Figure 1 Four depictions of indeterminate pulmonary
nodules. Grey arrow indicates the most commonly reported
trajectory of patient response; however, not all patients
experienced this ‘typical’ trajectory.
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Several individuals who displayed this depic-
tion described painful experiences with a parent
dying of cancer. They expressed a variety of
fears about cancer treatment (e.g. chemother-
apy, surgery), cancer death and what would
happen to their children if they died.
Depiction 2. Cognitive: I don’t know what it is;
Emotional: Fear/Worry
After their initial shock subsided, most patients
recognized that the diagnosis was not necessar-
ily cancer, and it was uncertain rather than
clearly malignant or benign. For many of our
participants, this uncertainty created substan-
tial anxiety.
It’s a scary roller coaster ride… I’ve never gotten
any definitive answers…And that’s scary in itself,
not knowing. [Pt2]
It can be traumatic when you think about it. …
If it’s not cancerous then it’s just a spot. It’s not
going to really bother you one way or another,
you can still live your life. If it’s the opposite,
then that’s when is it going to grow? [Pt7]
Most participants described spending a sub-
stantial amount of time distressed over not
knowing what the nodule was, even if they did
eventually move to a depiction associated with
greater equanimity.
Depiction 3. Cognitive: I don’t know what it is;
Emotional: Equanimity
By contrast, some were more comfortable with
the uncertainty of the diagnosis. They recog-
nized that the nodule might turn out to be can-
cer, but felt it was premature to worry about
something that had not yet happened and,
moreover, was beyond their control. This
depiction appeared to be more common among
older patients.
At my age [82 years], things are bound to go
wrong. … I don’t know if this thing is malignant,
or if it’s ever going to be malignant, something
else to get me worried. Let’s see how it plays
out. [Pt21]
I’m not living thinking that I’m going to get can-
cer from this. …Yes, there’s a possibility that I
could. But at that point in time I will deal with
it. I do not worry about something before it hap-
pens. [Pt4]
Depiction 4. Cognitive: It’s nothing serious;
Emotional: Equanimity
Shortly after learning about the nodule, some
dismissed it as a trivial health concern of little
significance, experiencing little distress. This
response was most common in patients with
substantial comorbid disease:
I had 2 heart attacks within one year. So I
could’ve died then, right? I won’t worry about
this little thing I’ve got on my lung. [Pt19]
These patients tended to worry more about
potential downsides of evaluation (e.g. radia-
tion exposure, medical expenses) than about
the nodule itself:
[The CTs are] a nuisance, taking up some of my
time. And I do worry about the radiation. …
That’s increasing my chances to get cancer
too. [Pt11]
Most patients in our study, however,
described coming to Depiction 4 more gradu-
ally, first fearing that the nodule was cancer
(Depiction 1), then processing the inherent
uncertainty of the nodule (Depictions 2 and 3),
before eventually accepting that it was not a
serious health threat (Fig. 1).
Moving towards ‘It’s Nothing Serious’:
influence of test results
The biomedical logic of surveillance holds that
the more time that passes without a clinical
change, the less likely the nodule is to be
malignant: in most cases, after 2 years without
growth, the nodule is deemed benign and
radiographic surveillance is terminated. Many
participants accepted this framework, reporting
that results from surveillance CTs helped to
change their perceptions of the nodule towards
less worrisome depictions. As time passed with
neither nodule growth nor onset of concerning
symptoms, they began to believe the nodule
was benign and ultimately felt equanimity
about it (Depiction 4):
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[When I first found out], I was going out the
window. But then they told me don’t worry
about it because … nothing’s changed. … Then
we just let it go. … That’s the way it is. [Pt10]
However, not every patient shared this way
of thinking. For some, subsequent tests with-
out biological change were not construed as
evidence of a benign aetiology and did not
diminish their concern: ‘It’s still the same size
… but it doesn’t reassure you … Some day
down the line, it could turn cancerous. Nobody
really knows’ [Pt13]. Some found tests indicat-
ing ‘no growth’ to be reassuring but brief
respites from chronic worry. These participants
expressed dissatisfaction with the usual 2-year
plan of surveillance; they wanted to monitor
the nodule for the rest of their lives or even to
undergo biopsy to lay the issue to rest:
I’m depending on them keeping check on it. See
if it’s enlarging or anything. [Pt8]
It really, really would be easier to know if you
had [cancer]. …If [my doctor] said, “Okay, you
can come in tomorrow to have a biopsy done,” I
would. [Pt20]
Managing the uncertainty
For many, undergoing surveillance entailed
chronic worry: ‘It’s nerve-wracking just to sit
and wait, …wondering when the bomb is going
to drop’ [Pt2]. Not content with the timeline of
clinical surveillance, patients used their own
approaches for coming to terms with the nod-
ule in the months between CT results. Some
approaches focused on trying to define the
nodule’s meaning to reduce uncertainty. Others
were aimed at mitigating the emotional
distress.
Vigilance for symptoms
Most patients reported monitoring themselves
for any change in symptoms, expressing a belief
that certain symptoms would signify nodule
growth (i.e. cancer): ‘Has it gotten any bigger?
… I don’t feel any different. My breathing is
good’ [Pt17]. For many, the absence of
symptoms mitigated their concern, but they
nonetheless remained vigilant for respiratory
symptoms that would warrant further work-up:
If I was having symptoms as a result of the nod-
ules, …I would probably be more concerned and
I would probably then think maybe a biopsy was
a good idea. [Pt4]
Most patients were unaware that a small
pulmonary nodule is unlikely to cause symp-
toms such as dyspnoea or pain, whether malig-
nant or not.
Information-seeking
Some patients tried to make sense of the nod-
ule by seeking additional information from cli-
nicians, friends or the internet:
I asked my doctor, but I was thinking, when I
get home, I will read more … like anyone with
the internet. [Pt16]
While some found additional information
reassuring, others reported it exacerbated their
uncertainty and distress: ‘in the computer …
they had a list of things that could happen. …
It scared you … It confuses you if you don’t
have a person there that knows what they’re
talking about’ [Pt6]. Several participants
reported that one reason they attended the
focus group was to obtain further information
about pulmonary nodules.
Contemplating risk factors
Participants considered a variety of possible
risk factors, many biomedically implausible,
that might explain how the nodule developed
and whether it was likely to be malignant.
Patients considered environmental, occupa-
tional, recreational and familial exposures, but
lingered on tobacco use, given its well-publi-
cized association with lung cancer.
Maybe it was the cigars that you’re not supposed
to inhale. … Everything has to be logical in my
world. [Pt7]
Tobacco use implied responsibility to
patients as well. Smokers expressed guilt, while
non-smokers expressed resentment that they
had developed a pulmonary problem.
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Avoidance
In contrast to those who spent time consider-
ing various aspects of the nodule and what it
might be, for some patients, the nodule was
simply too painful to contemplate.
Many strove to protect themselves by keep-
ing it out of their thoughts as much as possi-
ble: ‘I try to forget about this, because if I put
it in my head, I’m going to be like her, crying
all day and depressed’ [Pt18]. Several partici-
pants described exercising care when discussing
the nodule with friends or family, minimizing
its significance or providing qualifications to
protect themselves and their loved ones:
I don’t like to talk about it. If anything, I blow
it down, or I make sure I tell them comforting
words that the doctor said. … We all walk away
from it. [Pt3]
Some reported denying the nodule’s exis-
tence at times:
I know I don’t have anything. It must be a mis-
take, just a shadow. But it’s there, it’s there. You
have to deal with it. … It’s a painful diagnosis
[Pt1].
Controlling what they could
Several patients attempted to control all ele-
ments of the situation, believing that control-
ling the uncertainty of the situation would
render it less distressing. They began by reduc-
ing exposures they thought might cause the
nodule to become malignant (e.g. quitting or
cutting back on tobacco). Some expressed frus-
tration that, despite their best efforts, what
happened to the nodule was beyond their
control:
How can I control my lungs? I’m not smoking,
I’m not drinking, I have a healthy lifestyle. Exer-
cises, you know, eating the right organic food. …
[But] this is beyond my control. [Pt16]
Fate and faith
In contrast to those who tried to control the
situation, other patients found it useful to
accept that it was beyond their control. One
patient left the outcome of the nodule to ‘fate;’
others invoked their faith: ‘You’re kind of put
in the hands of God’ [Pt6]. For many, this
strategy resulted in a feeling of equanimity
towards the nodule.
Discussion
We have described the complex responses that
patients may have to the diagnosis and evalua-
tion of an indeterminate pulmonary nodule
and how they may develop over time. Several
patients presented perceptions that evolved
from an immediate fear about cancer (Depic-
tion 1); to a recognition of the inherent uncer-
tainty of the diagnosis, which tended to create
anxiety (Depiction 2); to an eventual accep-
tance that the nodule was no longer a health
threat (Depiction 4) after receipt of reassuring
test results and the passage of time (see arrow
in Fig. 1). However, the trajectory varied: some
never moved past the distressing conviction
that the nodule was cancer (Depiction 1), and
a few, while recognizing that cancer was a pos-
sibility, never experienced much distress over
the nodule (Depiction 3). Patients employed a
variety of coping strategies to inform their
evolving perceptions of the nodule, particularly
to resolve its unsettling uncertainty. Personal
experiences may also have informed patients’
depictions of the pulmonary nodule. For exam-
ple, family histories of cancer were linked to
fears that the nodule was malignant (Depiction
1), while older patients and those with substan-
tial comorbid disease expressed more equanim-
ity about the nodule (Depictions 3 and 4).
Perhaps, surprisingly, smoking status did not
appear to be associated with particular
response types: there were cases of smokers
and non-smokers who presented each depic-
tion. However, more subtle differences in
patient responses by smoking history might be
discovered if this topic was explored further in
a study focused on this topic.
The participants’ depictions of their nodules
echoed the common sense model of health
threats: cognitive formulations of what the
nodule might be and emotional responses to
it.13 Their stories highlighted the troubling
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problem presented by health threats that can-
not be named. A central theme in our analysis
was that patients’ inability to assign a clear
identity to the nodule (in their words, ‘not
knowing’) was the hardest part of living with
an indeterminate pulmonary nodule. Remark-
ably, some commented that it would be easier
to be told that they had cancer than to grapple
with the uncertainty of an indeterminate pul-
monary nodule. In many ways, these patients
acted as though they had been already given a
diagnosis of cancer. In the most extreme cases,
some made life changes to ‘prepare for the
worst’.14 Other coping strategies, also associ-
ated with a threat of cancer, included monitor-
ing themselves for symptoms that might
indicate the emergence of cancer,15,16 seeking
information about the diagnosis,16–19 contem-
plating risk factors for cancer20,21 and eliminat-
ing unhealthy exposures.15,20–22 Like cancer
patients and others facing an uncertain health
threat, some patients sought to avoid remind-
ers about the nodule16,23 or to surrender the
nodule and its health implications to fate or
faith.24,25 Some strategies (e.g. faith) appeared
to be more effective than others (e.g. informa-
tion-seeking) at resolving the distressing uncer-
tainty of the nodule, an area that warrants
further study.
This study has limitations. The experiences
reported by our focus group participants may
not speak for all individuals with pulmonary
nodules (e.g. we did not include individuals
with a high likelihood of a malignant nodule,
nor patients who had had a nodule detected
through lung cancer screening, which was not
routinely offered at the time of this study).
Patients who accepted the invitation to engage
in a focus group discussion may be more con-
cerned about their nodule than others who
declined to participate. Arguing against this
potential source of bias, some participants
reported very little distress about the nodule,
and some seemed almost indifferent towards it.
We cannot comment on the clinical significance
of the distress created by the uncertainty of an
indeterminate pulmonary nodule, nor on
whether individuals in our focus groups had
comorbid mental health issues that may have
led to a distress response that was both more
likely and more debilitating. However, other
studies have demonstrated that a broad cross
section of patients who have received abnormal
(though still indeterminate) cancer screening
test results experience distress that not only
adversely affects quality of life, but also can
lead to poor adherence with the evaluation of
potentially malignant findings.10,26,27 Finally,
we recognize that other factors beyond those
reported here likely influenced patient
responses. For example, we have explored
patients’ perceptions of the effects of their
doctors’ communication about the nodule
elsewhere.28
Despite these limitations, we believe our
results are an important addition to the litera-
ture, particularly in the light of newly released
guidelines for lung cancer screening that call
for clinicians to counsel patients on the trade-
offs of screening.29 An important downside to
lung cancer screening is the high false-positive
rate – in the National Lung Screening Trial,
39% of patients were found to have an indeter-
minate pulmonary nodule that required further
evaluation to rule out malignancy, and only
5% of these turned out to be cancer.30 As part
of shared decision making about lung cancer
screening, providers should discuss with
patients that there is a good chance an indeter-
minate pulmonary nodule will be found and
what evaluation of the nodule will entail. Our
findings draw attention to the intense distress
that some patients with an indeterminate pul-
monary nodule experience during surveillance,
a fact that clinicians should discuss with
patients considering lung cancer screening.
Although our results may not be generalizable
to patients who have a screen-detected (as
opposed to incidentally detected) pulmonary
nodule, surveys of individuals enrolled in trials
of lung cancer screening have shown increased
levels of distress related to the finding of an
indeterminate nodule.5,6
Moreover, our results may extend beyond
the specific instance of the indeterminate pul-
monary nodule to the broader scenario of how
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patients respond to an uncertain clinical find-
ing and the distress it may evoke.31 The pro-
found distress accompanying a clinically
uncertain diagnosis such as an abnormal cancer
screening test has been well documented.8–10,31
However, for many patients in this situation,
such as for women who have received a false-
positive mammogram, the uncertainty may be
intense, but it is quickly resolved through a
definitive biopsy showing that the lump is not
cancer. By contrast, prolonged uncertainty dur-
ing medical surveillance, such as that experi-
enced by patients with an indeterminate
pulmonary nodule or patients with low-grade
prostate cancer, can be particularly difficult for
patients.32 In the context of prostate cancer,
many men opt for definitive treatment despite
the risks of sexual and urinary dysfunction to
avoid the distress of ‘watchful waiting’ for a
known cancer.33–36 However, few studies have
taken an in-depth look at what surveillance for
an indeterminate result means for patients,
how the distress of an uncertain diagnosis
manifests itself for patients and the strategies
patients use to handle this uncertainty37 – par-
ticularly in the context of a diagnosis like an
indeterminate pulmonary nodule, which may
be a life-threatening cancer or nothing more
than a scar.
The way clinicians and patients perceive sur-
veillance may at times be at odds. Clinical sur-
veillance monitors the size of the nodule,
ending after 2 years without growth and a pre-
sumptive determination of a benign aetiology.
Surveillance as experienced by patients entails
a complicated vigilance, as patients grapple
with an unknown, potentially ominous threat
to life and well-being. Our data suggests that
routine surveillance and the findings of ‘no
growth’ are not always reassuring to patients
in the same way they are to clinicians, and that
patients may continue to engage in their own
version of surveillance long after the doctor
has terminated clinical surveillance. Hence,
effective, patient-centred communication
between doctors and patients is critical to
ensure that doctors and patients are on the
same page and that any misconceptions are
addressed. Without such clear communication,
neither informed nor shared decision making
can be achieved.
Patient-centred communication can, in prin-
ciple, help patients make sense of the nodule,
modulate its psychosocial sequelae and thereby
mitigate distress.38–40 Beyond the mere presen-
tation of facts about the nodule, which may
only highlight the cognitive uncertainty sur-
rounding what the nodule is and how best to
manage it,37 clinicians should recognize that
the uncertainty of an indeterminate pulmonary
nodule weighs heavily on some patients, and
offer emotional support to patients. Specific
communication strategies, including providing
clear information to patients, exploring the
patient’s values and attitudes and making man-
agement decisions collaboratively with the
patient, have been described as a means for cli-
nicians to mitigate the burden on patients of
an uncertain medical diagnosis.41–43 As has
been described in the context of prostate can-
cer,36 patients with indeterminate pulmonary
nodules want and need active surveillance, not
just ‘watchful waiting’ – and it is incumbent
upon clinicians to let them know what to
expect even before a screening test for lung
cancer is ordered.
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